Last checked at 26 Jun 2023 07:00
Creo Medical Group plc
("Creo" the "Company" or the "Group")
First upper GI Speedboat procedure in Europe completed days after clearance
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that Dr Adolfo Parra-Blanco, from Nottingham University Hospital NHS Trust has become the first clinician to perform an upper Gastrointestinal ("GI") tract Speedboat Inject case in Europe since clearance was gained last week.
The procedure saw a 7cm x 5cm cancerous lesion in the stomach removed en-bloc (in one piece) in a little under two hours and was performed after Dr Parra-Blanco led an Upper GI Endoscopy Education and Training Day at the University of Nottingham, where he was able to familiarise himself with the Speedboat Inject device for use in the upper GI tract.
The result of the procedure was excellent, with the patient leaving hospital shortly after.
A second doctor is now also trained to use Speedboat Inject for Upper GI procedures at Nottingham, and Nottingham University Hospital NHS Trust led Upper GI ESD courses showcasing Speedboat are set to take place next week (June 28-30) and in August at Queens Medical Centre, Nottingham. Creo will continue to work closely with Nottingham University Hospital NHS Trust to support the training, mentoring and adoption of the device by numerous upper GI specialists over the coming months. This will be in conjunction with Creo's Pioneer training programme, with the Company expecting a rapid adoption of the device for upper GI procedures over the coming months.
Dr Parra-Blanco said: "To have this technology now open to us for use in the upper GI in Europe is fantastic. What's clear to me is how well suited the Speedboat Inject device is for these types of procedures, and I foresee it dramatically increasing the number of patients able to benefit from this advanced energy, not only here in Nottingham but at healthcare settings elsewhere across Europe."
Craig Gulliford, Chief Executive Officer of Creo Medical said: "To have the first case completed at such a well-respected and prestigious endoscopic centre, renowned for its upper GI services, so soon after clearance demonstrates both the appetite for the device to be used in the upper GI tract in Europe and the ability for clinicians to quickly get optimal results once they are familiar with the advanced energy. We look forward to continuing to work with Nottingham University Hospital NHS Trust and others to maximise the roll out of the device in the entire GI tract."
Enquiries:
Creo Medical Group plc | www.creomedical.com |
Richard Rees (CFO) | +44 (0)1291 606 005 |
Cenkos Securities plc | +44 (0)20 7397 8900 |
Stephen Keys / Camilla Hume (NOMAD) | |
Michael Johnson / Russell Kerr (Joint Broker) | |
Numis Securities Limited (Joint Broker) | +44 (0)20 7260 1000 |
Freddie Barnfield / Duncan Monteith / Euan Brown | |
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus / Sam Allen / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com